Australia’s CSL said on Thursday its vaccine arm, CSL Seqirus and Vaccine Industrial Company, had inked a deal with Saudi Arabia’s Health Ministry to localize manufacturing of cell-based seasonal and pandemic influenza vaccines.
The deal comes a few days after biotech firm CSL said it was no longer targeting to complete the spin-off of Seqirus in fiscal 2026 amid heightened volatility in the U.S. vaccine markets.
CSL is now looking towards other regions for growth, while the U.S., its key vaccine market, saw an unprecedented fall in flu immunization rates, leading to Australia’s fourth-largest company by market value to dim its profit outlook for fiscal 2026.
Saudi Arabia Bets on 2026 Bird Flu Pandemic, Ramps Up Domestic Vaccine Production – modernity
Saudi Arabia has signed a Memorandum of Understanding with CSL Seqirus and Vaccine Industrial Company (VIC) to localize the production of “cell-based. H5N1 https://t.co/pHyLAl1fos
— Bird flu H5N1 (@Sushnov) October 30, 2025
h/t A Deplorable Neanderthal